Showing results (11-20 of 77) with videos related to
Sort By:
Pageof 8
Pituitary|April 14, 2007
Serum IGF-I levels in the diagnosis and monitoring of acromegalyA M Brooke, W M DrakeAnnales D'Endocrinologie|March 18, 2020
Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemiaC E Stiles, R P Steeds, W M DrakeClinical Therapeutics|May 17, 2001
Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000W M Drake, D L Kendler, J P BrownEuropean Journal of Endocrinology|August 19, 2008
Clinical use of cabergoline as primary and adjunctive treatment for acromegalyV J Moyes, K A Metcalfe, W M DrakeTrends in Endocrinology and Metabolism: TEM|October 12, 2001
Clinical use of a growth hormone receptor antagonist in the treatment of acromegalyW M Drake, C Parkinson, G M Besser, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|May 7, 2002
Use of phalangeal bone mineral density and multi-site speed of sound conduction to monitor therapy with alendronate in postmenopausal womenW M Drake, J P Brown, C Banville, et al.Clinical Endocrinology|November 26, 2015
Circadian variation in serum cortisol during hydrocortisone replacement is not attributable to changes in cortisol-binding globulin concentrationsT T Chung, K Gunganah, J P Monson, et al.Annals of the Royal College of Surgeons of England|October 24, 2015
Contemporary surgical treatment of primary hyperparathyroidism without intraoperative parathyroid hormone measurementO A Mownah, G Pafitanis, W M Drake, et al.European Journal of Endocrinology|August 3, 2005
Markers of cell proliferation in a GH-producing adenoma of a patient treated with pegvisomantW M Drake, D M Berney, K Kovacs, et al.Pageof 8